FALCO biosystems, Pharmaceutical Product Development to Collaborate in Development of Diagnostic Products for Renal Cancer.Tokyo, Japan, Dec 8, 2005 - (JCN JCN Japan Corporate NewsJCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - FALCO biosystems (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4671) announced on December 8 that it has concluded a joint develop agreement with US contract research organization (CRO) company Pharmaceutical Product Development (PPD (1) (Parallel Presence Detect) The method used by earlier SIMM memory modules to communicate their capacity to the computer. A binary number coming from a parallel set of pins was read by the system, with each pin representing one bit. Contrast with SPD. ). Under this agreement, the two companies will strive to develop diagnostic products for the detection of renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. . Specifically, PPD's biomarker discovery science group will identify biomarkers for renal cell carcinoma using its proprietary technologies in proteomics, peptidemics and metabolomics. PPD will own any intellectual properties derived from these analyses while FACLO will be exclusively licensed to use such intellectual properties in Japan. Financial terms of the agreement have yet to be disclosed. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion